Clinical Trial: GenAI-Assisted Rheumatoid Arthritis Bone Erosion Risk Assessment and DMARD Selection

U.S., Nov. 5 -- ClinicalTrials.gov registry received information related to the study (NCT07914907) titled 'GenAI-Assisted Rheumatoid Arthritis Bone Erosion Risk Assessment and DMARD Selection' on Oct. 21.

Brief Summary: Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by progressive joint damage and bone erosion. Accurate assessment of RA bone erosion risk (RABER) and appropriate disease-modifying antirheumatic drug (DMARD) selection are critical to preventing irreversible disability.

Recent advances in generative artificial intelligence (GenAI), particularly large language models (LLMs), enable integration of heterogeneous clinical data and may improve clinical decision-making. However, there is limited real-world...